Topical Gene Therapy Gets Priority Review for Dystrophic Epidermolysis Bullosa
B-VEC is an investigational topical gene therapy designed to deliver 2 copies of the COL7A1 gene when applied directly to DEB wounds.
B-VEC is an investigational topical gene therapy designed to deliver 2 copies of the COL7A1 gene when applied directly to DEB wounds.
In this interview, Paritosh Prasad, MD, provides insight into the recent outbreak of monkeypox.
Authors review the indications and contraindications, as well as the risks and benefits, of hyperbaric oxygen therapy in chronic wound management.
The approval was based on data from the phase 3 ADVANCE trial.
A 20-year-old woman presents to the dermatology clinic with a 5-day history of a mildly pruritic rash on both of her legs and feet. Can you diagnose this condition?
Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.
A 29-year-old man presents to the dermatology clinic for evaluation of a rash on his body that began 2 weeks ago. Can you make the diagnosis?
Previously unrecognized pathogenic mechanisms involving ocular contact dermatitis has driven new approaches to control the inflammatory process.
Clinician competence in treating patients of various racial and ethnic backgrounds and the critical need for greater inclusion of diverse populations in trials investigating the pathophysiology and treatment of AD are underscored.
A team of investigators sought to assess the relationship between thiazides, thiazide-like diuretics, or calcium channel blockers and the development of basal cell carcinoma, squamous cell carcinoma, or cutaneous malignant melanoma.